Adakveo generated $91.3 million in sales in the first quarter of 2024 [1]. This represents a 3% decrease compared to the same period in 2023, when sales reached $94.4 million [1].
How are Adakveo's sales trending over time?
Adakveo's sales in the first quarter of 2023 were $94.4 million [1]. For the first quarter of 2024, sales were $91.3 million [1]. This indicates a slight decline in revenue in early 2024 compared to the previous year [1].
Who manufactures Adakveo?
Adakveo is manufactured by Novartis [2].
What is Adakveo used to treat?
Adakveo (crizanlizumab-tmca) is a medication used to treat sickle cell disease (SCD) in adults and children 16 years of age and older [3]. It is administered as an intravenous infusion [3].
What are the alternatives to Adakveo for sickle cell disease?
Other treatments for sickle cell disease include hydroxyurea, L-glutamine, and voxelotor [4]. Recently, a gene therapy known as Casgevy has also been approved, offering a potential one-time curative treatment for eligible patients [5].
What is the mechanism of action for Adakveo?
Adakveo works by inhibiting P-selectin, a protein that plays a role in the inflammation and pain associated with sickle cell disease [3]. By blocking P-selectin, Adakveo aims to reduce the frequency of vaso-occlusive crises (VOCs), which are painful episodes caused by blocked blood flow [3].
What clinical data supports Adakveo's effectiveness?
The efficacy of Adakveo was evaluated in the SUSTAIN trial, a randomized, double-blind, placebo-controlled study [3]. This trial demonstrated that Adakveo significantly reduced the median annual rate of VOCs requiring medical attention compared to placebo in patients with sickle cell disease [3].
What are the potential side effects of Adakveo?
Common side effects of Adakveo include nausea, vomiting, diarrhea, abdominal pain, fever, back pain, chest pain, and dizziness [3]. Serious side effects can occur, including infusion reactions and potential effects on the immune system [3].
When did Adakveo receive FDA approval?
Adakveo received U.S. Food and Drug Administration (FDA) approval on November 25, 2019 [3].
What is the pricing for Adakveo?
Pricing information for Adakveo can vary and is typically discussed with healthcare providers and insurance companies. It is a high-cost medication, reflective of its specialized use in treating a chronic condition like sickle cell disease.
What are the patient concerns regarding Adakveo?
Patients may have concerns about the frequency of infusions, potential side effects, the long-term effectiveness of the treatment, and the cost of Adakveo. Discussions with healthcare providers are essential to address these concerns and determine if Adakveo is the appropriate treatment option [3].
What is the competitive landscape for Adakveo?
The market for sickle cell disease treatments is evolving with new therapies entering the space. While Adakveo targets vaso-occlusive crises, newer gene therapies like Casgevy offer a potentially curative approach, representing a significant shift in treatment paradigms [5]. Novartis also faces competition from other existing and pipeline treatments for SCD [4].
Sources
1. https://ir.novartis.com/news-releases/news-release-details/novartis-q1-2024-results
2. https://www.novartis.com/
3. https://www.adanvo.com/
4. https://www.nejm.org/doi/full/10.1056/NEJMoa2033351
5. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treatment-patients-sickle-cell-disease